Internship

Vertex Fall 2025 Co-op

Supply Chain & Manufacturing

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$20 - $35/hr

+ Bonus + Equity Awards

No H1B Sponsorship

Boston, MA, USA

Category
Supply Chain Management
Operations & Logistics
Required Skills
Supply Chain Management
Inventory Management
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Vertex Pharmaceuticals referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Enrolled in an undergraduate or graduate program in Supply Chain Management, Industrial Engineering, Finance, Business or related field
  • Displays ability to multi-task and prioritize work in a fast paced environment
  • Possesses strong organization skills
  • Possesses ability to work well both independently and in a team setting
  • Detail oriented
  • Has excellent written and verbal communication skills
  • Demonstrates the ability to assist in the execution of projects of diverse scope and complexity
  • Legal authorization to work in the United States, now and in the future
  • Candidate must be enrolled in an advanced degree program if graduating before July 2025
  • Candidate must be available to work full-time, 40 hours per week from July - December 2025
Responsibilities
  • Responsible for a wide variety of administrative activities within Commercial Supply Chain
  • Work closely with Finished Goods, Drug Product and Upstream Material teams to assess inventory levels, Open Purchase Orders and Material Movements
  • Create a reporting tool to track current and projected on-hand inventory levels with expiry and inventory value data
  • Manage operational excellence initiatives supporting manufacturing and/or supply chain
  • Take on a project to support process optimization efforts, including defining a problem, gathering customer requirements, measuring and analyzing processes, and implementing improvement projects
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's EU approval expands its cystic fibrosis treatment market.
  • Partnerships with Arbor and Orna enhance Vertex's gene therapy capabilities.
  • Increased focus on personalized medicine aligns with Vertex's patient-centric approach.

What critics are saying

  • Increased competition in cystic fibrosis could impact Vertex's market share.
  • Regulatory changes in the EU may delay Vertex's drug approvals.
  • High R&D costs and potential trial failures could strain Vertex's finances.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic partnerships for drug development.
  • Vertex's innovative cell and gene therapies set it apart in the biotech industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Buniversity
May 1st, 2025
VERTEX upset Grayhound for spot at BLAST Showdown

VERTEX locked in a first-place finish at Fortress OCE Masters Fall 2022 Finals in Melbourne to qualify for BLAST Premier Fall Showdown.

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.